Victory Capital Management Inc. boosted its position in shares of Immunomedics, Inc. (NASDAQ:IMMU) by 19.7% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,130,280 shares of the biopharmaceutical company’s stock after acquiring an additional 350,520 shares during the period. Victory Capital Management Inc.’s holdings in Immunomedics were worth $40,922,000 as of its most recent SEC filing.
Other large investors have also recently modified their holdings of the company. Dimensional Fund Advisors LP raised its holdings in shares of Immunomedics by 131.5% during the third quarter. Dimensional Fund Advisors LP now owns 199,337 shares of the biopharmaceutical company’s stock worth $4,152,000 after acquiring an additional 113,240 shares in the last quarter. Teachers Advisors LLC increased its position in Immunomedics by 6.4% during the third quarter. Teachers Advisors LLC now owns 271,649 shares of the biopharmaceutical company’s stock worth $5,658,000 after buying an additional 16,398 shares during the last quarter. Legal & General Group Plc increased its position in Immunomedics by 2.3% during the third quarter. Legal & General Group Plc now owns 48,707 shares of the biopharmaceutical company’s stock worth $1,014,000 after buying an additional 1,082 shares during the last quarter. Virtu Financial LLC acquired a new position in Immunomedics during the fourth quarter worth $257,000. Finally, Strs Ohio increased its position in Immunomedics by 3.0% during the fourth quarter. Strs Ohio now owns 76,651 shares of the biopharmaceutical company’s stock worth $1,093,000 after buying an additional 2,200 shares during the last quarter. 86.11% of the stock is owned by institutional investors.
Several equities analysts have commented on IMMU shares. BidaskClub downgraded shares of Immunomedics from a “buy” rating to a “hold” rating in a research report on Wednesday, February 13th. HC Wainwright set a $28.00 target price on shares of Immunomedics and gave the stock a “buy” rating in a research report on Tuesday, April 2nd. Zacks Investment Research downgraded shares of Immunomedics from a “hold” rating to a “sell” rating in a research report on Thursday, January 24th. ValuEngine downgraded shares of Immunomedics from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, April 24th. Finally, Cowen reissued a “buy” rating and set a $30.00 target price on shares of Immunomedics in a research report on Friday, January 18th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have given a buy rating to the company. Immunomedics presently has an average rating of “Buy” and an average target price of $28.45.
In other Immunomedics news, Director Avoro Capital Advisors Llc purchased 500,000 shares of the stock in a transaction dated Monday, May 13th. The shares were bought at an average cost of $15.07 per share, with a total value of $7,535,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 14.80% of the company’s stock.
Shares of NASDAQ:IMMU traded up $0.85 during midday trading on Thursday, hitting $15.78. The company’s stock had a trading volume of 95,064 shares, compared to its average volume of 3,111,805. The company has a market cap of $2.95 billion, a P/E ratio of -15.35 and a beta of 1.97. Immunomedics, Inc. has a fifty-two week low of $11.55 and a fifty-two week high of $27.33. The company has a debt-to-equity ratio of 0.04, a quick ratio of 7.89 and a current ratio of 7.89.
Immunomedics (NASDAQ:IMMU) last issued its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.36) by ($0.10). During the same quarter in the prior year, the business earned ($0.21) earnings per share. As a group, equities analysts predict that Immunomedics, Inc. will post -1.39 EPS for the current year.
Immunomedics, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. Its advanced antibody-drug conjugates are sacituzumab govitecan and labetuzumab govitecan, which are in advanced trials for various solid tumors and metastatic colorectal cancer, respectively.
Further Reading: Beige Book
Want to see what other hedge funds are holding IMMU? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Immunomedics, Inc. (NASDAQ:IMMU).
Receive News & Ratings for Immunomedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics and related companies with MarketBeat.com's FREE daily email newsletter.